These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29602612)

  • 1. To chelate or not to chelate in MDS: That is the question!
    Zeidan AM; Griffiths EA
    Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
    Gattermann N
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
    Zeidan AM; Pullarkat VA; Komrokji RS
    Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM; Komrokji RS
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
    Kattamis A; Aydinok Y; Taher A
    Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
    Mitchell M; Gore SD; Zeidan AM
    Expert Rev Hematol; 2013 Aug; 6(4):397-410. PubMed ID: 23991926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelation therapy in MDS: does it improve survival?
    Leitch HA
    Leuk Res; 2010 Jul; 34(7):852-3. PubMed ID: 20346508
    [No Abstract]   [Full Text] [Related]  

  • 11. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
    Leitch HA; Gattermann N
    Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
    Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
    Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation therapy in myelodysplastic syndromes.
    Fausel CA
    Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S10-4; quiz S16. PubMed ID: 20332500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload in myelodysplastic syndromes: diagnosis and management.
    List AF
    Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC; Wong SAY; Leitch HA
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG; Nagler A
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transfusions and iron chelation in myelodysplastic syndromes].
    Pascal L
    Bull Cancer; 2023 Nov; 110(11):1176-1182. PubMed ID: 37543453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.